Although Zoccali et al. [7] have questioned the previously reported protective cardiovascular impact of adiponectin in earlier stages of renal disease [5], available evidence indicates that highest total adiponectin increments are associated with lower cardiovascular risk in end-stage CKD [7-9]. The gene discussed is ADIPOQ; the disease is chronic kidney disease.